Clinical Trials Logo

Abortion, Spontaneous clinical trials

View clinical trials related to Abortion, Spontaneous.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 2

NCT ID: NCT04156126 Active, not recruiting - Infertility Clinical Trials

Measuring Immune Tolerance to Predict Miscarriage or Failed Embryo Transfer

Start date: August 23, 2019
Phase:
Study type: Observational

Pregnancy is a unique period which requires alterations in the immune system to allow for tolerance of a haploidentical fetus. The goal of this study is to measure maternal blood levels of proteins known to promote immune tolerance in early implantation and pregnancy to look for associations between tolerance, miscarriage and failed embryo transfer. Establishing predictive factors of miscarriage and failed in vitro fertilization could have implications for a large portion of couples and serve to guide current and future family planning efforts.

NCT ID: NCT03941470 Active, not recruiting - Clinical trials for Recurrent Miscarriage

Assessment of Natural Killer Cells in Unexplained Recurrent Pregnancy Loss

Start date: April 30, 2019
Phase:
Study type: Observational

To assess natural killer cells frequency and activation in cases of unexplained recurrent abortion in comparison to fertile cases - 2. . To study the expression of stimulatory receptors of natural killer cell. - 3-To study the expression of inhibitory receptors of natural killer cell.

NCT ID: NCT03736681 Active, not recruiting - Clinical trials for Abortion in First Trimester

Effect of Paracervical Block Volume on Pain Control for Dilation and Curettage

Start date: October 29, 2018
Phase: Phase 1
Study type: Interventional

The investigators are conducting a study on pain control for dilation and curettage (D&C). Participants are eligible to enroll if they are a planning to have a D&C in a participating clinic. The investigators are studying how different ratios of medication to liquid affect pain when injected around the cervix. Both potential methods use the same dose of medication, though researchers would like to know which one works better. To be in this study, participants must be over the age of 18 with an early pregnancy loss or undesired pregnancy measuring less than 12 weeks gestation undergoing D&C while awake in clinic.

NCT ID: NCT03165136 Active, not recruiting - Clinical trials for Recurrent Miscarriage

Hydroxychloroquine for Prevention of Recurrent Miscarriage.

BBQ
Start date: December 4, 2017
Phase: Phase 3
Study type: Interventional

Recurrent miscarriage (RM) defined by >=3 consecutive losses affects 1% of fertile couples. Most women have recurrent early loss with a failure of development before 10 weeks' gestation. Standard investigations fail to reveal any apparent cause in >50% of couples. No study has demonstrated any benefit of any medication in women with Unexplained RM, in the presence or absence of an inherited thrombophilia. Moreover, the benefit of aspirin and/or heparin has not been proved in women with Antiphospholipid (APL) antibody without other clinical manifestations of Antiphospholipid Syndrome. Hydroxychloroquine (HQ) is a molecule whose properties (anti-thrombotic, vascular-protective, immunomodulatory, improved glucose tolerance, lipid-lowering, anti-infectious) could be useful against mechanisms of Unexplained RM. There is no data concerning the benefit of HQ in RM in the presence or absence of antiphospholipid antibodies or any inherited thrombophilia. Administration in (Systemic Lupus erythematosus (SLE) women and for Malaria prevention provides extensive safety data during pregnancy. Oral administration makes possible treatment since the preconception period. For all of that and its low cost, hydroxychloroquine should be evaluated in RM whatever the woman thrombophilic status.

NCT ID: NCT02434900 Active, not recruiting - Clinical trials for Abortion, Spontaneous

Vitamin D and Angiogenic Markers in Odense Child Cohort 1

VITAM
Start date: January 2010
Phase: N/A
Study type: Observational [Patient Registry]

The Vitamin D and Angiogenic Marker Study 1: Vitamin D and angiogenic markers in early pregnancy. Epidemiology and associations to early-pregnancy miscarriage

NCT ID: NCT02156063 Active, not recruiting - Clinical trials for Recurrent Pregnancy Loss

A Multi-center, Placebo-controlled Study to Evaluate NT100 in Pregnant Women With a History of Unexplained Recurrent Pregnancy Loss (RPL)

RESPONSE
Start date: June 2014
Phase: Phase 2
Study type: Interventional

This is a randomised, double blind, multi-center, placebo-controlled study of subcutaneous NT100 in pregnant women with a history of unexplained recurrent pregnancy loss. Approximately 150 participants will be randomised to receive subcutaneous NT100 or placebo.

NCT ID: NCT01419392 Active, not recruiting - Clinical trials for Recurrent Miscarriage

Role of Sildenafil Citrate in Patients With Unexplained Recurrent Miscarriages

Start date: September 2011
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether sildenafil citrate is effective in improving uterine artery blood flow and oxidative stress in patients with unexplained recurrent miscarriages